Cargando…

On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target

Cryptosporidium parvum is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bo, Yan, Yueyang, Wang, Dongqiang, Zhang, Ying, Yin, Jigang, Zhu, Guan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079235/
https://www.ncbi.nlm.nih.gov/pubmed/36972284
http://dx.doi.org/10.1371/journal.pntd.0011217
_version_ 1785020690187943936
author Yang, Bo
Yan, Yueyang
Wang, Dongqiang
Zhang, Ying
Yin, Jigang
Zhu, Guan
author_facet Yang, Bo
Yan, Yueyang
Wang, Dongqiang
Zhang, Ying
Yin, Jigang
Zhu, Guan
author_sort Yang, Bo
collection PubMed
description Cryptosporidium parvum is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens, it is important to validate whether the observed anti-infective activity is attributed to the drug action on the pathogen or host target. For the epicellular parasite Cryptosporidium, we have previously developed a concept that the host cells with significantly increased drug tolerance by transient overexpression of the multidrug resistance protein-1 (MDR1) could be utilized to evaluate whether and how much the observed anti-cryptosporidial activity of an inhibitor was attributed to the inhibitor’s action on the parasite target. However, the transient transfection model was only applicable to evaluating native MDR1 substrates. Here we report an advanced model using stable MDR1-transgenic HCT-8 cells that allows rapid development of novel resistance to non-MDR1 substrates by multiple rounds of drug selection. Using the new model, we successfully validated that nitazoxanide, a non-MDR1 substrate and the only FDA-approved drug to treat human cryptosporidiosis, killed C. parvum by fully (100%) acting on the parasite target. We also confirmed that paclitaxel acted fully on the parasite target, while several other inhibitors including mitoxantrone, doxorubicin, vincristine and ivermectin acted partially on the parasite targets. Additionally, we developed mathematical models to quantify the proportional contribution of the on-parasite-target effect to the observed anti-cryptosporidial activity and to evaluate the relationships between several in vitro parameters, including antiparasitic efficacy (EC(i)), cytotoxicity (TC(i)), selectivity index (SI) and Hill slope (h). Owning to the promiscuity of the MDR1 efflux pump, the MDR1-transgenic host cell model could be applied to assess the on-parasite-target effects of newly identified hits/leads, either substrates or non-substrates of MDR1, against Cryptosporidium or other epicellular pathogens.
format Online
Article
Text
id pubmed-10079235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100792352023-04-07 On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target Yang, Bo Yan, Yueyang Wang, Dongqiang Zhang, Ying Yin, Jigang Zhu, Guan PLoS Negl Trop Dis Research Article Cryptosporidium parvum is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens, it is important to validate whether the observed anti-infective activity is attributed to the drug action on the pathogen or host target. For the epicellular parasite Cryptosporidium, we have previously developed a concept that the host cells with significantly increased drug tolerance by transient overexpression of the multidrug resistance protein-1 (MDR1) could be utilized to evaluate whether and how much the observed anti-cryptosporidial activity of an inhibitor was attributed to the inhibitor’s action on the parasite target. However, the transient transfection model was only applicable to evaluating native MDR1 substrates. Here we report an advanced model using stable MDR1-transgenic HCT-8 cells that allows rapid development of novel resistance to non-MDR1 substrates by multiple rounds of drug selection. Using the new model, we successfully validated that nitazoxanide, a non-MDR1 substrate and the only FDA-approved drug to treat human cryptosporidiosis, killed C. parvum by fully (100%) acting on the parasite target. We also confirmed that paclitaxel acted fully on the parasite target, while several other inhibitors including mitoxantrone, doxorubicin, vincristine and ivermectin acted partially on the parasite targets. Additionally, we developed mathematical models to quantify the proportional contribution of the on-parasite-target effect to the observed anti-cryptosporidial activity and to evaluate the relationships between several in vitro parameters, including antiparasitic efficacy (EC(i)), cytotoxicity (TC(i)), selectivity index (SI) and Hill slope (h). Owning to the promiscuity of the MDR1 efflux pump, the MDR1-transgenic host cell model could be applied to assess the on-parasite-target effects of newly identified hits/leads, either substrates or non-substrates of MDR1, against Cryptosporidium or other epicellular pathogens. Public Library of Science 2023-03-27 /pmc/articles/PMC10079235/ /pubmed/36972284 http://dx.doi.org/10.1371/journal.pntd.0011217 Text en © 2023 Yang et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yang, Bo
Yan, Yueyang
Wang, Dongqiang
Zhang, Ying
Yin, Jigang
Zhu, Guan
On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title_full On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title_fullStr On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title_full_unstemmed On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title_short On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target
title_sort on-target inhibition of cryptosporidium parvum by nitazoxanide (ntz) and paclitaxel (ptx) validated using a novel mdr1-transgenic host cell model and algorithms to quantify the effect on the parasite target
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079235/
https://www.ncbi.nlm.nih.gov/pubmed/36972284
http://dx.doi.org/10.1371/journal.pntd.0011217
work_keys_str_mv AT yangbo ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget
AT yanyueyang ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget
AT wangdongqiang ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget
AT zhangying ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget
AT yinjigang ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget
AT zhuguan ontargetinhibitionofcryptosporidiumparvumbynitazoxanidentzandpaclitaxelptxvalidatedusinganovelmdr1transgenichostcellmodelandalgorithmstoquantifytheeffectontheparasitetarget